Daryl T.‐Y. Lau, Bruce A. Luxon, Shu‐Yuan Xiao, Michael R. Beard, Stanley M. Lemon – 28 June 2005 – To gain insight into pathogenic mechanisms underlying fibrosis in hepatitis C virus (HCV)‐mediated liver injury, we compared intrahepatic gene expression profiles in HCV‐infected patients at different stages of fibrosis and α‐smooth muscle actin (α‐SMA) staining patterns. We studied 21 liver biopsy specimens: 5 had no fibrosis (Ludwig‐Batts stage 0); 10 had early portal or periportal fibrosis (stages 1 and 2); and 6, advanced fibrosis (stages 3 and 4).

Nicola Villanova, Simona Moscatiello, Stefano Ramilli, Elisabetta Bugianesi, Donatella Magalotti, Ester Vanni, Marco Zoli, Giulio Marchesini – 24 June 2005 – Nonalcoholic fatty liver disease (NAFLD) is consistently associated with features of the metabolic syndrome, a condition carrying a high risk of cardiovascular events. We measured the vasodilatory response of the brachial artery in response to ischemia (a test of endothelial function) (FMV) as well as cardiovascular risk profile in 52 NAFLD cases and 28 age‐ and sex‐matched controls.

Savita Srivastava, Zobair M. Younossi – 23 June 2005

Luis Ruiz‐del‐Arbol, Alberto Monescillo, Carlos Arocena, Paz Valer, Pere Ginès, Víctor Moreira, José María Milicua, Wladimiro Jiménez, Vicente Arroyo – 23 June 2005 – The pathogenic mechanism of hepatorenal syndrome is not well established. We investigated the circulatory function in cirrhosis before and after the development of hepatorenal syndrome.

George M. Lauer – 22 June 2005 – By necessity, human liver transplantation is performed across HLA barriers. As a result, intracellular infection of the allograft presents a unique immunologic challenge for the recipient's immune system. In this study, we describe the presence of HLA‐A2‐restricted, hepatitis C virus (HCV)‐specific CD8+ T cells in liver transplant recipients in whom the allograft is HLA‐A2 positive and the recipient is HLA‐A2 negative. These memory‐effector T cells are recipient derived and recognize HCV peptide uniquely in the context of HLA‐A2.

Elizabeth Anne Pomfret – 22 June 2005

Pieter Evenepoel, Bert Bammens, Frederik Nevens, Alexander Wilmer, Yves Vanrenterghem – 22 June 2005

Matthew R. Foxton, Lisa Knight, Alex S. Knisely, Ghulam J. Mufti, John O'Grady, Paolo Muiesan, Suzanne Norris – 22 June 2005 – End‐stage liver disease due to chronic hepatitis C virus (HCV) infection is now the most frequent indication for liver transplantation. HCV infection is associated with extrahepatic disease including cryoglobulinemia and lymphoma.

Mauricio Orrego, Linsheng Guo, Craig Reeder, Giovanni De Petris, Vijayan Balan, David D. Douglas, Thomas Byrne, Edwyn Harrison, David Mulligan, Hector Rodriguez‐Luna, Adyr Moss, Kunam Reddy, Jorge Rakela, Hugo E. Vargas – 22 June 2005 – B‐cell non‐Hodgkin's lymphoma (B‐NHL) is a well‐documented complication of hepatitis C virus (HCV) infection. Marginal zone (mucosa‐associated lymphoid tissue; MALT) lymphomas constitute a less common type of B‐NHL. In this article, we report a case of liver MALT in a cirrhotic patient, incidentally discovered after liver transplantation (LT).

22 June 2005